PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
- RADIATION: Stereotactic Body Radiotherapy (SBRT)
- DRUG: Darolutamide 600 mg twice daily
- DRUG: Androgen Deprivation Therapy (ADT)
Sponsor
West China Hospital
Collaborators